MSD DPP-4 inhibitor doesn’t increase CV risk in diabetes, heart patients

A major study of 14,671 patients from 38 countries with type 2 diabetes and established cardiovascular disease has found that a DPP-4 inhibitor does not increase the risk for major adverse CV events, hospitalisation for heart failure or adverse events. The study was published in the NEJM this week and presented at the American Diabetes